Glucagen Hypokit

Glucagen Hypokit is a prescription glucagon product marketed in the European Union. The active ingredient is glucagon, a peptide hormone used to raise blood glucose. The kit is supplied in a ready‑to‑use format for intramuscular, intravenous, or subcutaneous injection. Exact strength and dosage form are not specified in the public summary, but the product is classified as an Rx medication for emergency treatment of severe hypoglycemia.

Glucagen Hypokit is indicated for the rapid reversal of severe hypoglycemia when oral carbohydrate intake is not possible or effective.

- Acute treatment of insulin‑induced hypoglycemia in diabetic patients. - Emergency management of hypoglycemia in patients with adrenal insufficiency or other endocrine disorders. - Use in hospital or pre‑hospital settings when immediate glucose elevation is required. - Administration by trained personnel during a hypoglycemic crisis. - Suitable for patients of all ages who can receive an injectable glucagon preparation.

The safety profile of glucagon includes both frequently observed reactions and rare but serious events.

Common: - Nausea, vomiting, or abdominal discomfort that usually resolves quickly. - Flushing, warmth, or a feeling of heat at the injection site. - Headache or dizziness occurring shortly after administration. - Transient increase in blood pressure or heart rate. - Local injection site pain or bruising that is typically mild and short‑lasting. - Transient sweating or feeling of anxiety during the glucose‑raising response.

Serious: - Severe allergic reactions such as anaphylaxis, characterized by rash, swelling, or difficulty breathing. - Cardiac disturbances including arrhythmias, chest pain, or myocardial ischemia, especially in patients with pre‑existing heart disease. - Hypoglycemia rebound after initial glucose increase, requiring monitoring and possible repeat dosing.

When using Glucagen Hypokit, healthcare providers and patients should observe several precautions to ensure safe and effective administration.

- Verify the diagnosis of severe hypoglycemia before administration. - Use only with a compatible glucagon delivery device and follow the manufacturer’s instructions. - Assess for known hypersensitivity to glucagon or any excipients. - Monitor blood glucose levels after injection to confirm response. - Avoid use in patients with pheochromocytoma or insulinoma without specialist guidance. - Store the kit according to label conditions, protecting it from moisture and extreme temperatures.

Glucagon may interact with certain medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concomitant use of beta‑blockers that may mask typical glucagon‑induced tachycardia. - Administration with drugs that cause severe hypertension, such as monoamine oxidase inhibitors, without monitoring.

Use with caution: - Patients receiving oral hypoglycemic agents; monitor for recurrent hypoglycemia after glucagon effect wanes. - Individuals with cardiovascular disease; observe for arrhythmias or chest discomfort. - Use in pregnant or lactating women only when the benefit outweighs potential risk, as safety data are limited.